Role of Combination Chemotherapy with 5-Fluorouracil, Cisplatin and Paclitaxel for Advanced Gall Bladder Cancer


Aim: The prognosis for patients with advanced Gallbladder carcinoma is poor. Due to unresectability and relatively ineffective chemotherapy available, a need exists for effective chemotherapeutic regimen. The aim of this study was to determine the efficacy and safety profile of 5-fluorouracil, cisplatin and paclitaxel in patients with advanced Gallbladder cancer. Material and Methods: From January 2002 to July 2004, 40 patients of advanced carcinoma Gallbladder received 5-fluorouracil, cisplatin and paclitaxel. On day 1, paclitaxel was given (150 mg/m2), cisplatin was given on day 2 (50 mg/m2) and 5-fluorouracil was given from day 1 to day 3 (500 mg/m2). This cycle was repeated every three weeks and patient assessment was done. Results: Forty patients were enrolled in this study. Thirty-five were assessed for response. Five patients were lost in follow up. There were thirty females and ten males. A median of three cycles of treatment (range one to seven) was administered. Two patients achieved complete response and eleven had partial responses giving an overall response rate of 32.5% in the intention-to-treat population (95% confidence interval 11.1% to 46.5%). The median response duration was 5.3 months. The median time to progression and overall survival was 4.1 months and 11.2 months, respectively. The most common grade 3 adverse effects were neutropenia (30%), nausea (20%), vomiting (15%), diarrhea (10%), stomatitis (5%), and peripheral neuropathy (5%). Only one case had febrile neutropenia. There was no treatment related death. Conclusions: The combination of 5-fluorouracil, cisplatin and paclitaxel has promising anti-tumor activity and is well tolerated in patients with advanced and metastatic Gallbladder cancer.

Share and Cite:

Ansari, M. , Tiwary, S. , Shahi, U. and Shukla, V. (2014) Role of Combination Chemotherapy with 5-Fluorouracil, Cisplatin and Paclitaxel for Advanced Gall Bladder Cancer. Journal of Cancer Therapy, 5, 246-252. doi: 10.4236/jct.2014.53032.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Glimelius, B., Hoffman, K., Sjoden, P.O., Jacobsson, G., Sellstrom, H., Enander, L.K., Linne, T. and Svensson, C. (1996) Chemotherapy Improves Survival and Quality of Life in Advanced Pancreatic and Biliary Cancer. Annals of Oncology, 7, 593-600. a010676
[2] Takada, T., Nimura, Y., Katoh, H., Nagakawa, T., Nakayama, T., Matsushiro, T., Amano, H. and Wada, K. (1998) Prospective Randomized Trial of 5-Flurouracil, Doxorubicin and Mitomycin C for Non-Rescctable Pancreatic and Biliary Carcinoma: Multicenter Randomized Trial. Hepatogstroenterology, 45, 2020-2026.
[3] Falkson, G., Mac Intyre, J.M. and Moertel, C.G. (1984) Eastern Cooperative Oncology Group Experience with Chemotherapy for Inoperable Gallbladder and Bile Duct Cancer. Cancer, 54, 985-969.<965::AID-CNCR2820540603>3.0.CO;2-X
[4] Davis Jr., H.L., Ramirez, G. and Ansfield, F.J. (1974) Adenocarcinomas of Stomach, Pancreas, Liver, and Biliary Tracts. Survival of 328 Patients Treated with Fluoropyrimidine Therapy. Cancer, 33, 193-197.<193::AID-CNCR2820330128>3.0.CO;2-S
[5] Okada, S., Ishii, H., Nose, H., Okusaka, T., Kyogoku, A., Aoki, K., Iwasaki, M., Furuse, J. and Yoshino, M. (1994) A Phase II Study of Cisplatin in Patients with Biliary Tract Carcinoma. Oncology, 51, 515-517.
[6] Ducreux, M., Rougier, P., Fandi, A., Yoshimori, T., Wakabayashi, K., Clavero-Fabri, M.C., Villing, A.L., Fassone, F., Fandi, L., Zarba, J. and Armand, J.P. (1998) Effective Treatment of Advanced Biliary Tract Carcinoma Using 5-Fluorouracil Continuous Infusion with Cisplatin. Annals of Oncology, 9, 653-656.
[7] Doval, D.C., Shekhon, J.S., Gupta, S.K., Fuloria, J., Shukla, V.K., Gupta, S. and Awasthy, B.K. (2004) A Phase II Study of Gemcitabine and Cisplatin in Chemotherapy—Naive Advanced Unresectable Gall Bladder Cancer. British Journal of Cancer, 90, 1516-1520.
[8] Thongprasert, S., Napapan, S., Charoentum, C. and Moonprakan, S. (2005) Phase II Study of Gemcitabine and Cisplatin as First Line Chemotheraphy in Inoperable Biliary Tract Carcinoma. Annals of Oncology, 16, 279-281.
[9] Malik, I.A., Aziz, Z. and Zaidi, Sethumaran, G. (2003) Gemcitabine and Cisplatin Is a Highly Effective Combination Therapy in Patients with Advanced Cancer Gall Bladder. American Journal of Clinical Oncology, 26, 174-177.
[10] Eng, C., Ramnathan, R.K., Wong, M.K., Ramick, S.C., Dai, L., Wade-Oliver, K.T., Mani, S. and Kindler, H.L. (2004) A Phase II Trial of Fixed Dose Rate Gemictabine in Patients with Advanced Biliary Carcinoma. American Journal of Clinical Oncology, 27, 565-569. 00135924.94955.16
[11] Di lauro, L., Carpano, S., Capomolla, E., et al. (1997) Cisplatin, Epirubicin and 5-Fluorouracil (PEF) for Advanced Biliary Tract Carcianoma. American Society of Clinical Oncology, 16, 287 a.
[12] Okada, S., Okusaka, T., Ishii, H., et al. (1997) Phase II Trial of Cisplatin, Epirubicinss and Continuous Infusion 5-Fluorouracil (5-FU) (CEF Fherapy) for Advanced Gall Bladder Cancer (GBC). American Society of Clinical Oncology, 16, 301 a.
[13] Ellis, P.A., Norman, A., Hill, A., O’Brien, M.E., Nicolson, M., Hickish, T. and Cunningham, D. (1995) Epirubicin, Cisplatin and Infusional 5-Fluorouracil (5-FU) (ECF) in Hepatobiliary Tumours. European Journal of Cancer, 31A, 1594-1598.
[14] Ishii, H., Furuse, J., Yonemoto, N., Nagase, M., Yoshino, M. and Sato, T. (2004) Chemotherapy in Treatment of Advanced Gallbladder Cancer. Oncology, 66, 138-142. 0077440
[15] Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Verweij, J., Van Glabakke, M., Van Oosterom, A.T., Christian, M.C. and Gyther, S.G. (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute, 92, 205-221.
[16] Gehan, E.A. (1961) The Determination of the Number of Patients Required in a Preliminary and Follow-Up Trial of a New Chemotherapeutic Agent. Journal of Chronic Diseases, 13, 346-353.
[17] Penz, M., Kornek, G.V., Raderer, M., Ulrich-Pur, H., Fiebiger, W., Lenauer, A., Depish, D., Krauss, G., Schneweiss, B. and Scheithauer, W. (2001) Phase II Trial of Two Weekly Gemcitabine in Patients with Advanced Biliary Tract Cancer. Annals of Oncology, 12, 183-186. 8352123009
[18] Lin, M.H., Chen, J.S., Chen, H.H. and Su, W.C. (2003) A Phase II Trial of Gemictabine in Treatment of Advanced Bile Duct and Periampullary Carcinomas. Chemotherapy, 49, 154-158.
[19] Taieb, J., Mitry, E., Boige, V., Artru, P., Ezenfis, J., Lecomte, T., Claverno-Fabri, M.C., Vaillant, J.N., Rougier, P. and Ducreux, M. (2002) Optimization of 5-Flurouraicl (5-FU)/Cisplatin Combination Chemotherapy with a New Schedule of Leucovorin, 5-FU and Cisplatin (LV5FU 2-P Regimen) in Patients with Biliary Tract Carcinoma. Annals of Oncology, 13, 1192-1196.
[20] Patt, Y.Z., Hassan, M.M., Lozano, R.D., Waugh, K.A., Hoque, A.M., Frome, A.I., Lahoti, S., Ellis, L., Vauthey, J.N., Curley, S.A., Schnirer, I.I. and Raijman, I. (2001) Phase II Trial of Cisplatin, Interferon Alpha-2 b, Doxorubicin and 5-Fluorouracil for Biliary Tract Cancer. Clinical Cancer Research, 7, 3375-3380.
[21] Gupta, S.K., Ansari, M.A. and Shukla, V.K. (2005) What Makes the Gangetic Belt a Fertile Ground for Gallbladder Cancers? Journal of Surgical Oncology (In press),
[22] Parikh, P.M., Agarwalla, D.K., Malhotra, H., Govindbabu, K., Ranade, A.A., Vaid, A.K., Basade, M. and Bhattacharyya, G.S. (2005) Gallbladder and Biliary Tract Carcinoma—A Comprehensive Medical Management Update. Indian Co-Operative Oncology Network.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.